Pulmonary aspergillosis after treatment with infliximab in Still's disease and a literature review of Still's disease and pulmonary aspergillosis

ŞEYHOĞLU E., ERDEN A., KILIÇ L., KARADAĞ Ö., ARIKAN AKDAĞLI S., AKDOĞAN A., ...More

EUROPEAN JOURNAL OF RHEUMATOLOGY, vol.5, no.1, pp.75-78, 2018 (ESCI) identifier

  • Publication Type: Article / Review
  • Volume: 5 Issue: 1
  • Publication Date: 2018
  • Doi Number: 10.5152/eurjrheum.2016.15081
  • Journal Name: EUROPEAN JOURNAL OF RHEUMATOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.75-78
  • Hacettepe University Affiliated: Yes

Abstract

The use of anti-tumor necrosis factor alpha (anti-TNF-alpha) agents has increased during the past decade in rheumatology practice. Opportunistic infections have been reported with anti-TNF-alpha agents in clinical trials and post-marketing usage. Aspergillus infection is a rare opportunistic infection that is associated with immunosuppression, and there are reported cases of pulmonary aspergillosis in various rheumatic diseases treated with anti-TNF-alpha agents. Here, we present the first case of pulmonary aspergillosis associated with infliximab treatment in a patient with Still's disease.